An interventional study of blood sampling in HIV Infection, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by ANRS, Emerging Infectious Diseases · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases — 12 open to participants now, 13 under way, none of them phase 3. HIV Infections · ANRS, Emerging Infectious Diseases.
Among the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, this one is the 14th largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2012, is one of 24 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 23rd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →12 of the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases are open now, in 2 countries. Recruiting first, the newest first:
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18+
ANRS, Emerging Infectious Diseases
Ages 21+
ANRS, Emerging Infectious Diseases
Ages 13–18
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18+ · Women only
ANRS, Emerging Infectious Diseases
Ages 18+
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 13
First in 1997; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 207 across the 50 interventional studies, 488 across the 22 observational. Of the 47 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.
3 of the studies in HIV Infections by ANRS, Emerging Infectious Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07770568ANRS, Emerging Infectious DiseasesDetection of Specific Metabolic Signatures by Nuclear Magnetic Resonance or Metabolomic NMR in Correlation With Markers of Inflammation or Immune Activation and the Risk of Developing Neurocognitive Disorders - Longitudinal Retrospective Study Nested in the ANRS12225 PEDIACAM III Cohort | 2027-03 |
| NCT06913959ANRS, Emerging Infectious DiseasesHIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) | 2027-07-01 |
| NCT06338826ANRS, Emerging Infectious DiseasesStudy Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A consortium of research teams has studied the immunovirological characteristics of these patients:
The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
Two cohorts of patients with a phenotype of HIV resistance exist in France. The ANRS CO15 ALT cohort was set up in 1994. 71 patients were enrolled defined on immunological criteria: CD4 T cell count above 600/mm3 with a stable or increasing count (positive or zero slopes) on at least three consecutive exams performed during the last 5 years whatever the viral load was, with a known HIV infection for at least 8 years. A consortium of research teams has studied the immunovirological characteristics of these patients. After 16 years of follow-up, 6 patients are still actively followed. The main results have shown the lack of deletion in viral genes nor any functional viral defects, a small size for the viral reservoir, and distinctive genetic characteristics of the host (HLA, chemokines) which lead to potent immune cell responses associated with virus control.
The ANRS CO18 HIV Controller cohort set up in 2009 is stemming from the French National Observatory of HIV Controllers which was active between 2006 and 2008 (Study ANRS EP36). 152 patients are enrolled who are defined on virological criteria: the last 5 plasmatic viral loads should be below 400 copies/mL without any antiretroviral treatment, in HIV-infected patients for more than 5 years. A consortium of research teams has studied these patients and has shown that Controllers are infected with replication-competent HIV, that HIV infects CD4 T cells but that the viral replication in CD4 T cells is fully controlled by CD8 T cells.
In addition, the ANRS EP47 VISCONTI study identified 14 patients who had been able to maintain plasmatic viral loads below 400 copies/ml for more than 7 years in the absence of antiretroviral treatment. Differently from HIV controllers, naïve of antiretroviral treatment, the patients from the VISCONTI study started therapy within ten weeks of primary infection and kept it for a median of three years before treatment discontinuation (Post-Treatment Controllers or PTC). The initial analyses revealed important clinical and immunogenetic differences between post-treatment and natural controllers, suggesting that PTC were not naturally predispose to control infection and that they succeeded thanks to initial therapeutic intervention. The mechanisms associated with long-term control in post-treatment controllers also appear different from the main mechanisms identified in HIV controllers. The main objective now is to gather in a common cohort patients with a particular resistance to HIV infection, either with an immunological control (ALT) or a natural (HIV Controllers) or induced virological control (PTC). The enrolled patients will be the patients already enrolled in the cohorts CO15 and CO18, the ANRSEP47 VISCONTI study, and new patients. This will allow common physiopathological studies to precise the mechanisms leading to the virus control and CD4 homeostasy. A better knowledge of the mechanisms of viral control and immune response preservation is very important in the setting of vaccine perspectives and in the perspective of implementing new therapeutic interventions to induce remission of HIV infection. This cohort will allow common research projects with common funding, a better visibility both for clinicians who see patients with unusual phenotypes and for international research. Such a cohort will be unique in the world by its size and the presence of these three complementary groups of patients. The two main objectives for the " Extreme " cohort (ANRS CO21 CODEX) are clinical and immunovirological. We wish to precise the impact of a prolonged untreated HIV infection, to describe the frequency of the "immunological escapes" (CD4 T cell decrease) or "virological escapes" (permanent or transient viral load increase), and to identify predictive markers of HIV control. We wish to study the genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ALT group: Documented HIV-1 seropositive for at least 8 years with a above 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years regardless of the viral load in the absence of antiretroviral treatment
HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the last 5 viral loads in HIV-RNA consecutive \<400 copies / mL regardless of CD4 count in the absence of antiretroviral treatment
ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years and with the last 5 viral loads in HIV-RNA consecutive \<400 copies / mL in the absence of antiretroviral therapy.
PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of antiretroviral therapy. Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an incomplete P24-positive Western blot) or during the chronic phase of infection, and maintained for at least 12 months in both cases. Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be \<400 copies/mL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies/mL between two viral loads \<400 copies/mL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be \<400 copies/mL
Exclusion Criteria:
Under protection(saving) of justice
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood sampling
Biological: blood sampling
blood sampling
clinical and immuno-virological
Time frame: up to 5 years
mechanisms leading to the virus control and CD4 homeostasy with physiopathological studies
Time frame: up to 5 years
impact of a prolonged untreated HIV infection,
Time frame: up to 5 years
frequency of the "immunological escapes" (CD4 T cell decrease) or "virological escapes" (permanent or transient viral load increase)
Time frame: up to 5 years
genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control
Time frame: up to 5 years
Started Feb 2012 (actual). Primary completion is estimated for Sep 2029, 211 months after the start.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 211 months is above that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ANRS, Emerging Infectious Diseases →